CDC, FDA recommend lifting Johnson & Johnson’s COVID-19 Vaccine following pause

CDC, FDA recommend lifting Johnson & Johnson’s COVID-19 Vaccine following pause

Last updated:

Learn our story about how we are independent and what is needed to keep thisquality operating. You might be able to donate to us so we can inform and share what matters faster.

Learn Morearrow

The Centers for Disease Control and Prevention and the Food and Drug Administration recommended in a statement on Friday that Vaccine providers should resume their use of the Johnson & Johnson jabs.

An Advisory Committee on Immunization Practices had said the one-dose shot is reportedly safe enough to continue use and make available again at Vaccine sites.

This is despite the risk that blood clots can occur, but chances are ‘very low’ according to Acting FDA Commissioner Janet Woodcock during the conference yesterday.


“Together, both agencies have full confidence that this vaccine’s known and potential benefits outweigh its known and potential risks in individuals 18 and older,” said Woodcock.

Per one million people, the rate of blood clots is around 1.9 who get vaccinated. 15 recipients who took the Vaccine developed the rare blood clot causing three to die and hospitalising seven. They were mostly under the age of 50 and were women.

Rates from ages 18-49 show seven cases per one million for women, and those that are over the age of 50 is .9 cases per one million.

Benefits associated with the Vaccine reportedly outweigh the risks. Dr Peter Marks, the Director of the FDA’s Center for Biologics Evaluation and Research, says the drug will likely get back into arms, “probably by tomorrow morning even.”

Only 15 injuries were found, including three deaths upon the examination of seven million vaccinations following a pause last week. This occurred after six women under the age of 48 developed rare blood clots, including one that died due to inoculation.

Five were discharged from Hospital, while six remain hospitalized. Thirteen of the cases were found in women between the ages of 17 and 49, while two occurred in females over the age of 50.

Surprisingly, no cases were found in men except for one that occurred during clinical trials. The examination concludes out of the seven million vaccinations that it is safe for use for those over the age of 18.

Image: Gettyimages

Have time to spare? If you liked this publication, please learn our story to support thisquality. Fund trustworthy news coming from official Government newswires and local voices inside communities.


COVID-19 Coverage

Alert Level 1: PREVENT
*All of New Zealand
*The button below directs to Government Unite Against COVID-19 website.

Notify of
Inline Feedbacks
View all comments